BCR and B-cell chronic lymphocytic leukemia: Inhibitors such as Idelalisib, which target the phosphatidylinositol-3-kinase (PI3K) isoform p110δ (PI3K δ) downstream of the BCR, have numerous effects on CLL progression [19–21].